The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.

The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ETCompany ParticipantsStephen Hoge - PresidentConference ...

An optimal mix of gut bacteria (microbiome) found in infants born vaginally could help children fight off severe viral lower ...

In 2022, Europe experienced the biggest diphtheria outbreak in the region in 70 years, and authors writing yesterday in the ...